Related Experiment Video
Updated: Jun 18, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
[Cabergoline in hyperprolactinemia and valvular heart disease].
Marcos Lahera Vargas1, Carlos Escobar Cervantes, Carmen Alameda Hernando
1Servicio de Endocrinología y Nutrición, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, España. marcos.lahera@salud.madrid.org
Summary
Low-dose cabergoline for hyperprolactinemia appears safe for cardiac valves, with no clinically significant regurgitation found in a systematic review. Mild tricuspid regurgitation was noted but remained asymptomatic.
Area of Science:
- Endocrinology
- Cardiology
Background:
- High-dose cabergoline is linked to cardiac valve issues in Parkinson's disease.
- The safety of low-dose cabergoline for cardiac valves in hyperprolactinemia requires investigation.
Purpose of the Study:
- Systematically analyze reports on low-dose cabergoline treatment for hyperprolactinemia.
- Evaluate the impact of low-dose cabergoline on cardiac valve function.
Main Methods:
- Systematic analysis of seven reports.
- Inclusion of 463 patients treated with low-dose cabergoline for hyperprolactinemia.
Main Results:
- No clinically significant cardiac valve regurgitation was observed.
- Mild tricuspid regurgitation was reported in two studies, and moderate in one.
- Valve thickening and increased mitral tenting area were rarely documented.
Conclusions:
- Low-dose cabergoline is generally safe for hyperprolactinemia patients.
- Asymptomatic tricuspid regurgitation may be more prevalent but is not clinically significant.
- Further longitudinal studies are recommended, with caution advised for high-dose cabergoline users.
Related Concept Videos
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.